medigraphic.com
ISSN 1405-1710 (Print)

2012, Number 3

<< Back Next >>

Rev Cent Dermatol Pascua 2012; 21 (3)

Graft versus host disease

Domínguez GMA, Rodas-Díaz AC

Language: Spanish
References: 19
Page: 104-108
PDF size: 119.53 Kb.


ABSTRACT

Allogeneic bone marrow transplantation is used as a treatment for malignancies of hematopoietic origin, in some solid tumors and autoimmune diseases. Graft versus host disease (GVHD) develops as a frequent complication of this treatment. The initial term of GVHD was proposed by Billingham in 1966. GVHD was originally divided into acute and chronic, depending on whether the presentation is before or after the fi rst 100 days of transplantation. In this article we report the case of a patient with GVHD who progressed well with the treatment.


REFERENCES

  1. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: clinical manifestation and therapy. Minireview. Bone Marrow Transplant 2001; 28: 121-129.

  2. Snover DC. Acute and chronic graft versus host disease: histopathological evidence for two distinct pathogenetic mechanisms. Human Pathol 1984; 15: 202-205.

  3. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330: 827-838.

  4. Rodríguez-García H, Velásquez-González E, Magaña-Ramírez MC et al. Enfermedad injerto contra huésped. Dermatología Rev Mex 2006; 50(5): 174-184.

  5. Johnson ML, Farmer ER. Graft-versus–host reactions in dermatology. J Am Acad Dermatol 1998; 38(3): 369-392.

  6. Aractingi S, Chosidow O. Cutaneous graft-versus–host disease. Arch Dermatol 1998; 134(7): 602-612.

  7. Tabbara S, Zimmerman K, Morgan C et al. Hematopoietic stem cell transplantation. Arch Intern Med 2002; 162(14): 1558-1566.

  8. Beirana PA, Alcalá-Pérez D, Franco-Castro A. Enfermedad injerto contra huésped. Rev Cent Dermatol Pascua 2000; 9(2): 74-80.

  9. Marra DE, McKee PH, Nghiem P. Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. J Am Acad Dermatol 2004; 51(4): 543-546.

  10. Deeg HJ, Antin JH. The clinical spectrum of acute graft-versus-host disease. Semin Hematol 2006; 43(1): 24-31.

  11. Pérez-Simón JA. Enfermedad injerto contra huésped crónica: fisiopatología, clasificación y tratamiento. Hematológica 2009; 94: 61.

  12. Horwitz ME, Sullivan KM. Chronic graft-versus-host disease. Blood Reviews 2006; 20: 15–27.

  13. Gilliam AC. Update chronic graft-versus-host disease. JID 2004; 123: 251-257.

  14. Gilligan AC, Whitaker-Menezes D, Korngold R et al. Apoptosis is the predominant form of epithelial target cell in acute experimental graft-versus-host disease. J Invest Dermatol 1996; 107: 377-383.

  15. Sedghizadeh PP, Allen CA, Anderson KE et al. Oral graft-versus host disease and programmed cell death: Pathogenetic and clinical correlates. Oral Surg Oral Med Oral Pathol Radiol Endod 2004; 97: 491-498.

  16. Schaffer JV. The Changing face of graft-versus-host disease. Semin Cutan Med Surg 2006; 25: 190-200.

  17. Easaw SJ, Lake DE, Beer M et al. Graft-versus-host disease. Possible higher risk for African American patients. Cancer 1996; 78: 1492-1497.

  18. Centeno A, Ruiz Lascano A. Variedad esclerodermiforme de enfermedad injerto contra huésped. Med Cutan Iber Lat Am 2006; 34: 21-24.

  19. Rojas K, Pacheco M, Pajuelo M. Enfermedad injerto contra huésped crónica refractaria. Folia Dermatol Perú 2008; 19(2): 81-84.




2020     |     www.medigraphic.com